Literature data describe the existence of a correlation between chemotherapeutic agents effectiveness and "non-TF" protein variants expression, such as the androgen receptor isoform AR-V7 and abiraterone/enzalutamide in patients with castration-resistant prostate cancer [179] or BRCA1-delta11q and PARP inhibitors/cisplatin in breast cancer [180]. This evidence concerns the gene TF and breast carcinoma.